New data debuted by the UK’s BioIndustry Association (BIA) has hinted towards the recovery of the British biotech financing market, which an expert says could help shift attention away from fundraising to focus on advancing R&D.
In the BIA’s Q1 2026 biotech financing report, the trade body noted that the total equity financing raised by UK companies was £552m ($746m) – marking a 18% uptick from the £466m ($632m) raised in Q4 2025.
Meanwhile, venture capital (VC) raising also saw a 17% boost, with British biotechs securing £516m ($699m) in Q1 2026, comparted to £442m ($599m) in Q4 2025. While the value of VC funds in Q1 didn’t eclipse the £924m ($1.25bn) total raised in the same period in 2025, there was a broader distribution of capital across companies, with 25 businesses securing funding in 2026 compared with 15 in Q1 2025.
Of these fundings, rounds from Series B and beyond pulled in the largest share of the cash at £276m ($374m) across three deals – highlighting the continued investor appetite for mature assets. According to the BIA, this highlights the burgeoning trend towards fewer large financings by investors, who are instead focusing on selective, smaller capital allocations.
IPO market remains dormant, but M&A thrives
Despite the generally positive trends for UK biotech in Q1, this has not extended to the public markets. With follow-on financing totalling just £36m and no British companies going public, UK activity has remained stagnant across the quarter.
While the BIA’s director of policy and external affairs, Martin Turner tells Pharmaceutical Technology there is likely no cut-and-dry way to improve this situation, he notes that future changes could hinge on the Nasdaq IPO window opening up, as well as the trend towards investors adapting to geopolitical uncertainty.
Though British biotechs are hesitant to go public, there has been some healthy M&A activity across the country, with Eli Lilly buying UK-based sleep drug biotech, Centessa Pharmaceuticals, for $7.8bn in April, while Amgen scooped up oncology specialist, Dark Blue Therapeutics, for $840m in January.
As per the BIA, these deals highlight the continued interest in British biotechs and their science, despite the public financing challenges faced by the sector.
Implications of UK biotech's Q1 success
In conversation with Pharmaceutical Technology, Turner noted that a second quarter of increased fundraising and an improvement in the spread of this investment allows executives to increasingly shift their focus to the science.
“There are more management teams now in a position to focus on progressing their R&D programmes rather than fundraising, which is good for the growth and success of the sector in 2026, and of course for patients waiting for new treatments,” Turner said.
According to Turner, the strength of financing in the UK versus the rest of Europe also shines a positive light on Britain’s future prospects, as it will “further reinforce global attention” on the UK life sciences ecosystem. This comes as experts warn that both powers are at risk of falling behind dominant forces like China and the US as the funding landscape proves challenging to navigate.
Keeping up the positive trend
To continue the upward financing trend for biotech in the UK, Turner says the British government must show it can deliver its commitments laid out in the Life Sciences Sector Plan, as well as its agreement with the US to raise the National Health Service’s (NHS) spending on medicines.
“The government must show that it is a stable and reliable partner for the life sciences sector in an increasingly unstable world,” Turner states.
In a bid to boost the competitiveness of the UK’s life sciences sector, the government is also looking to streamline its clinical trial setup process through the 10 Year Health Plan, while focusing on making the NHS an attractive location for innovation through the National Cancer Plan for England and the National Healthtech Access Programme (NHAP).
To reach its full potential, experts previously told Pharmaceutical Technology that the UK must focus on creating a “launch market” for innovative drugs, while curating a favourable business environment that champions diversity and provides attractive tax rates for businesses.
